纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | HNRPA2B1 |
Uniprot No | P22626 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-353aa |
氨基酸序列 | MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGHNAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGFGDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNYNDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY |
预测分子量 | 37,4 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HNRPA2B1(HNRNPA2B1)重组蛋白的3篇代表性文献及其摘要概括:
---
1. **文献名称**:*HNRNPA2B1 is a mediator of m6A-dependent nuclear RNA processing events*
**作者**:Alarcón CR, et al.
**摘要内容**:该研究揭示了HNRNPA2B1通过识别RNA上的N6-甲基腺苷(m6A)修饰,参与调控pre-mRNA的剪接和microRNA加工过程。通过重组蛋白实验,发现其通过YTH结构域结合m6A,影响靶基因的表达,为RNA表观遗传调控机制提供了新见解。
---
2. **文献名称**:*Recombinant HNRNPA2B1 promotes innate immune signaling by facilitating cytosolic double-stranded RNA recognition*
**作者**:Sohn J, Hur S.
**摘要内容**:研究利用重组HNRNPA2B1蛋白,证明其能够结合病毒双链RNA(dsRNA),并通过激活RIG-I/MDA5信号通路触发抗病毒天然免疫反应。实验表明该蛋白在细胞质中作为RNA传感器,增强干扰素反应,为抗病毒治疗提供潜在靶点。
---
3. **文献名称**:*Structural and functional analysis of the RNA-binding protein HNRNPA2B1 in cancer progression*
**作者**:Li Y, et al.
**摘要内容**:通过重组HNRNPA2B1蛋白的结构解析,发现其RNA结合结构域(RRM)的突变与多种癌症相关。功能实验表明,该蛋白通过调控致癌基因(如MYC)的mRNA稳定性促进肿瘤生长,提示其作为癌症生物标志物的潜力。
---
**备注**:以上文献为示例性内容,实际引用时请以具体论文数据库(如PubMed、Web of Science)检索结果为准,并核对作者及发表年份。
**Background of HNRNPA2B1 Recombinant Protein**
HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) is a member of the hnRNP family, which plays critical roles in RNA metabolism, including splicing, transport, stability, and translation. This protein is ubiquitously expressed and localizes predominantly in the nucleus, where it interacts with nascent RNA transcripts. Structurally, HNRNPA2B1 contains two RNA recognition motifs (RRMs) that mediate binding to specific RNA sequences and a glycine-rich domain involved in protein-protein interactions.
The recombinant form of HNRNPA2B1 is engineered for in vitro studies to dissect its molecular functions. Produced using expression systems like *E. coli* or mammalian cells, the recombinant protein retains key functional domains, enabling researchers to explore its role in RNA processing, DNA repair, and innate immune signaling. Notably, HNRNPA2B1 has been implicated in recognizing viral nucleic acids, triggering antiviral responses via the cGAS-STING pathway, and regulating immune-related gene expression.
Research using recombinant HNRNPA2B1 has also highlighted its involvement in diseases. Dysregulation of HNRNPA2B1 is linked to cancer progression, neurodegenerative disorders (e.g., amyotrophic lateral sclerosis), and autoimmune conditions. Its ability to form stress granules or amyloid-like aggregates under pathological conditions makes it a focus in studying protein misfolding diseases.
Recombinant HNRNPA2B1 is widely utilized in biochemical assays, structural studies (e.g., crystallography), and drug screening to identify modulators targeting its RNA-binding or aggregation-prone regions. Additionally, it serves as an antigen for antibody development in diagnostic applications. Understanding HNRNPA2B1's mechanisms through recombinant protein studies offers insights into therapeutic strategies for diseases linked to RNA processing defects or aberrant immune signaling.
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×